Miércoles 01/07/20 Reporte del empleo privado

[admin]

https://money.cnn.com/data/dow30/

[admin]

Stocks rise on positive coronavirus vaccine news, Pfizer gains
PUBLISHED TUE, JUN 30 20206:03 PM EDTUPDATED 23 MIN AGO
Fred Imbert
@FOIMBERT
Yun Li
@YUNLI626
Stocks traded higher on Wednesday to kick off the second half of 2020 with market sentiment getting a lift from positive coronavirus vaccine news and strong U.S. payrolls data.

The Dow Jones Industrial Average rose 72 points, or 0.3%. The S&P 500 climbed 0.2% and the Nasdaq Composite was flat.


A study of a coronavirus vaccine candidate being developed by Pfizer and BioNTech showed the drug created neutralizing antibodies. The results were released online, but have not been reviewed by a medical journal yet.

“We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings,” said Kathrin U. Jansen, head of vaccine research and development at Pfizer, in a release.

The company also said that, if the vaccine get regulatory approval, it expects to make up to 100 million doses by year-end and “potentially” more than 1.2 billion by the end of 2021. Pfizer shares jumped more than 6% on the news and BioNTech’s U.S.-listed shares were halted following an 8.1% pop.

CNBC’s Jim Cramer said on “Squawk on the Street” that Pfizer is seen as credible so investors will like the news. “This is highly unlike Pfizer ... I, frankly, don’t want to accept it like this, but the market will and it’s kind of a saved-by-Pfizer market from where we were,” said Cramer.

Pfizer and BioNTech’s news comes as more than 12 states have now paused or rolled back their reopenings, with cases in the U.S. jumping 40% over the past week to an average of about 39,750 on Monday, according to a CNBC analysis of data compiled by Johns Hopkins University.

Shares of companies that would benefit from the economy reopening rose on Wednesday. United Airlines gained 7.5% and Delta climbed 3.3%. Cruise operator Carnival advanced 4.9% and Royal Caribbean advanced 7.4%. Retailer Kohl’s climbed 2.4%.

White House health advisor Dr. Anthony Fauci warned Tuesday that if the outbreak continues at its current pace, daily new cases could surpass 100,000 new infections per day.

“We continue to expect it to be an uneven process, albeit with a positive trajectory,” Keith Lerner, chief market strategist at SunTrust Advisory Services, said in a note. “The good news is through this digestion period, markets are working off some of the excesses that had built up, and elevated expectations are being reset.”

Wall Street was coming off its best quarterly performance in decades. The Dow notched Tuesday its biggest one-quarter surge since 1987. The S&P 500 and Nasdaq had their best quarters since 1998 and 1999, respectively.

Big ADP revision

ADP and Moody’s Analytics said private payrolls jumped by 2.37 million in June. Payrolls for May were also revised to a gain of more than 3 million from a loss of 2.76 million.

The market just notched its best quarter in decades as it snapped back from the historic sell-off triggered by the coronavirus. The Dow gained 17.8% in the second quarter, posting its best quarter since 1987, while the S&P 500 finished the period with a near 20% gain, its best since 1998. The tech-heavy Nasdaq soared 30.6% for the quarter, the most since 1999.

FedEx jumped nearly 11% after posting quarterly earnings and revenue that topped analysts’ forecast. The shipping company experienced a surge in deliveries amid the coronavirus lockdown.


Subscribe to CNBC PRO for exclusive insights and analysis, and live business d

[admin]

LAST CHG %CHG
DJIA 25832.43 19.55 0.08
S&P 500 3111.57 11.28 0.36
Nasdaq Composite 10110.66 51.90 0.52
Japan: Nikkei 225 22121.73 -166.41 -0.75
UK: FTSE 100 6183.39 13.65 0.22
Crude Oil Futures 39.30 0.03 0.08
Gold Futures 1774.10 -26.40 -1.47
Yen 107.47 -0.46 -0.43
Euro 1.1260 0

[admin]

AST CHG %CHG
DJIA 25835.96 23.08 0.09
S&P 500 3111.71 11.42 0.37
Nasdaq Composite 10111.28 52.52 0.52
Japan: Nikkei 225 22121.73 -166.41 -0.75
UK: FTSE 100 6180.33 10.59 0.17
Crude Oil Futures 39.16 -0.11 -0.28
Gold Futures 1773.50 -27.00 -1.50
Yen 107.50 -0.44 -0.40
Euro 1.1258 0

[admin]

LAST CHG %CHG
DJIA 25821.77 8.89 0.03
S&P 500 3115.18 14.89 0.48
Nasdaq Composite 10135.43 76.67 0.76
Japan: Nikkei 225 22121.73 -166.41 -0.75
UK: FTSE 100 6157.96 -11.78 -0.19
Crude Oil Futures 39.85 0.58 1.48
Gold Futures 1777.40 -23.10 -1.28
Yen 107.45 -0.48 -0.44
Euro 1.1261

[admin]

Copper July 01,12:39
Bid/Ask 2.7365 - 2.7370
Change -0.0075 -0.27%
Low/High 2.7189 - 2.7694
Charts

Nickel July 01,12:38
Bid/Ask 5.8293 - 5.8315
Change +0.0448 +0.77%
Low/High 5.7181 - 5.8383
Charts

Aluminum July 01,12:36
Bid/Ask 0.7244 - 0.7246
Change +0.0006 +0.08%
Low/High 0.7198 - 0.7279
Charts

Zinc July 01,12:38
Bid/Ask 0.9158 - 0.9160
Change -0.0070 -0.76%
Low/High 0.9086 - 0.9363
Charts

Lead July 01,12:39
Bid/Ask 0.8013 - 0.8016
Change -0.0033 -0.40%
Low/High 0.7955 - 0.8166
Charts

Uranium Jun 22, 2020
Ux U308 price: 32.80
Change from

[admin]

https://lta.reuters.com/articulo/salud- ... 26PG-OUSLT

[admin]

https://lta.reuters.com/articulo/econom ... AKBN2426HS

[admin]

https://lta.reuters.com/articulo/salud- ... 26BY-OUSLT

[admin]

Pfizer stock jumps after it reports positive data in early stage coronavirus vaccine trial
PUBLISHED WED, JUL 1 20209:05 AM EDTUPDATED 36 MIN AGO
Berkeley Lovelace Jr.
@BERKELEYJR
Pfizer shares jumped after it released positive results from its closely watched early stage human trial on a coronavirus vaccine.
The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.
Pfizer said the vaccine was generally well tolerated, though the experimental vaccine also caused fever in some patients, especially for those who were in the 100 microgram group.
WATCH NOW
VIDEO01:27
Pfizer, BioNTech see early positive results for Covid-19 vaccine candidate
Pfizer shares jumped 4% Wednesday after it released positive results from its closely watched early stage human trial of a coronavirus vaccine.

The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.


The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data. The findings were posted in a paper released on MedRXiv. The company said the levels of neutralizing antibodies were 1.8 to 2.8 times higher than in recovered Covid-19 patients.

After 28 days, all participants in the two lower-dose groups had significant levels of binding antibodies, the company said.

“We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings,” Kathrin Jansen, head of Pfizer’s vaccine research and development, said in a press release. “We are dedicated to develop potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency.”

The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany.
The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany.
Thomas Lohnes | Getty Images
The U.S.-based pharmaceutical giant has been working alongside German drugmaker BioNTech. The companies’ experimental vaccine contains genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response to the virus.

Pfizer said the vaccine was generally well tolerated, though the experimental vaccine caused fever in some patients, especially for those who were in the 100 microgram group. Most patients reported pain at the injection site, which was mild to moderate, the company said, except in one of 12 subjects who received a 100 microgram dose, which was severe.


The findings posted Wednesday have not been peer-reviewed yet.

The effort by Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has infected more than 10 million people worldwide and killed at least 511,851, according to data compiled by Johns Hopkins University. There are more than 100 vaccines currently under development, according to the World Health Organization.

Another leading vaccine candidate from biotech firm Moderna is expected to enter a late-stage trial later this month, pending the results from its mid-stage trial. If all goes well in Moderna’s next trial, its vaccine could be available for public distribution by the end of the year.

A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020.
A woman holds a small bottle labeled with a “Vaccine COVID-19” sticker and a medical syringe in this illustration taken April 10, 2020.
Dado Ruvic | Reuters
Hopes to get a vaccine to market are high, but scientists are setting expectations low for how quickly it can happen. Developing, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take years, global health experts say.

Dr. Anthony Fauci, the nation’s leading infectious disease expert, has said he is “cautiously optimistic” scientists can find a safe and effective vaccine by early 2021.

Scientists hope the antibodies provide some degree of protection against getting Covid-19, but they can’t say that definitively yet since the virus was first discovered just six months ago. It hasn’t been studied in-depth and some patients appear to have been reinfected after recovering from Covid-19.

A recent study published in Nature Medicine found coronavirus antibodies may last only two to three months after a person becomes infected with Covid-19. Researchers examined 37 asymptomatic people, those who never developed symptoms, in the Wanzhou District of China. They compared their antibody response to that of 37 people with symptoms.

Scientists conducting larger vaccine studies later this year hope to answer lingering questions about Covid-19 antibodies.

Pfizer said it expects to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021. The company intends to begin a mid-stage trial as early as this month.

[admin]

LAST CHG %CHG
DJIA 25811.07 -1.81 -0.01
S&P 500 3115.25 14.96 0.48
Nasdaq Composite 10141.33 82.56 0.82
Japan: Nikkei 225 22121.73 -166.41 -0.75
UK: FTSE 100 6157.96 -11.78 -0.19
Crude Oil Futures 39.68 0.41 1.04
Gold Futures 1781.70 -18.80 -1.04
Yen 107.46 -0.47 -0.44
Euro 1.1256

[admin]

LAST CHG %CHG
DJIA 25838.41 25.53 0.10
S&P 500 3119.95 19.66 0.63
Nasdaq Composite 10152.11 93.35 0.93
Japan: Nikkei 225 22121.73 -166.41 -0.75
UK: FTSE 100 6157.96 -11.78 -0.19
Crude Oil Futures 39.81 0.54 1.38
Gold Futures 1780.30 -20.20 -1.12
Yen 107.44 -0.49 -0.45
Euro 1.1258 0.0022

[admin]

LAST CHG %CHG
DJIA 25839.92 27.04 0.10
S&P 500 3126.55 26.26 0.85
Nasdaq Composite 10194.92 136.15 1.35
Japan: Nikkei 225 22121.73 -166.41 -0.75
UK: FTSE 100 6157.96 -11.78 -0.19
Crude Oil Futures 39.82 0.55 1.40
Gold Futures 1781.00 -19.50 -1.08
Yen 107.46 -0.47 -0.44
Euro 1.1256

[admin]

CHG %CHG
DJIA 25734.97 -77.91 -0.30
S&P 500 3115.86 15.57 0.50
Nasdaq Composite 10154.63 95.86 0.95
Japan: Nikkei 225 22121.73 -166.41 -0.75
UK: FTSE 100 6157.96 -11.78 -0.19
Crude Oil Futures 39.71 0.44 1.12
Gold Futures 1780.90 -19.60 -1.09
Yen 107.47 -0.46 -0.42
Euro 1.1252 0

[admin]

https://www.wsj.com/articles/inside-mod ... 05?mod=mhp